Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years

Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic protein, frequently overexpressed in hematological malignancies. Venetoclax was approved by the Food and Drug Administration for chronic lymph...

詳細記述

書誌詳細

主要な著者:	Alexis Talbot, Pierre-Edouard Debureaux, Agnès Lillo-Le Louet, Yasmine Derri, Marine Aroux-Pavard, Hélène Jantzem, David M. Smadja, Cyrille Touzeau, Christine Le Beller, Nicolas Gendron
フォーマット:	Artigo
言語:	Inglês
出版事項:	SAGE Publishing 2025-07-01
シリーズ:	Therapeutic Advances in Hematology
オンライン･アクセス:	https://doi.org/10.1177/20406207251343116
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!